Navigation Links
Foundation® Posterior Stabilized Knee

ProductsFoundation® Posterior Stabilized Knee
Company Encore Medical Corporation
Item Foundation® Posterior Stabilized Knee
Features 
  • Multiple patella options available.
  • All polyethylene options with cement grooves.
  • Metal-backed Ti6A14V option.
  • Three peg fixation.
  • Two thickness options for all poly patella.
  • Symmetrical flange design.
    • Description The Foundation® PS knee offers a femoral option and tibial insert which provides a specially designed cam action that engages at 60 degrees of flexion to induce a smooth stable femoral roll-back motion and allow for 130 degrees of flexion. Femoral component comes in a PS open box design with prominent lateral flare. The constrained tibial insert in conjunction with the femur is designed to maximize "in-plane" joint motion while minimizing "out-of-plane" translation and rotation.
    Info Encore Medical Corporation
    Customer Service: (800) 456-8696
    Web site: http://www.encoremed.com/

    Related medicine products :

    1. Foundation® Knee CR System
    2. Foundation® Modular Revision System
    3. Holladay Posterior Capsule Polisher and Curette
    4. Posterior Capsule Polisher, 23 g
    5. Posterior Capsule Polisher, 21 g
    6. Simcoe Posterior Chamber Lens Forceps
    7. Spine-Tract Posterior Lumbar Retractor System
    8. Image-Trac Posterior Spine Retractor System
    9. Graftech Posterior Ramp
    10. Tangent Posterior Impacted Instrument Set
    11. TANGENT Posterior Impacted Instrument Set
    Breaking Medicine Technology:Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3Dendreon Announces Webcast Presentations at Upcoming Investor Conferences 13867 1Women Urged Not to Drink While Pregnant 56308 1Women Urged Not to Drink While Pregnant 56308 2Women Urged Not to Drink While Pregnant 56308 3Amgen to Present at the Baird Healthcare Conference 56306 1Amgen to Present at the Baird Healthcare Conference 56306 2